Adial Pharmaceuticals, Inc. Beat Consensus Estimates
Thursday, May 15, 2025 at 8:30 AM ET
Adial Pharmaceuticals, Inc. (ADIL) reported a loss of $0.34 per share on revenue of $0.00 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.50 per share. The company beat consensus estimates by 32.00%.
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-0.34
Earnings Whisper®
-
Consensus Estimate
$-0.50
Earnings Surprise
Earnings Growth
Reported Revenue
-
Revenue Estimate
-
Revenue Surprise
Revenue Growth